• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
COVID-19 Management

Is There a Link Between COVID-19 Vaccines and Facial Nerve Paralysis?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE: 

  • Peripheral facial nerve (Bell’s) palsy has been reported and widely suggested as a possible adverse effect of the Pfizer-BioNTech COVID-19 vaccine 
  • Shemer et al. (JAMA Otolaryngology Head Neck Surgery, 2021), assessed whether COVID-19 mRNA vaccination was associated with facial nerve palsy in a case-control study 

METHODS: 

  • Case-control study 
  • Setting 
    • Israel 
  • Population 
    • Patients admitted for facial nerve palsy matched with control patients by age, sex, and date of admission 
  • Exposures 
    • Recent COVID-19 vaccination with Pfizer-BioNTech  
  • Primary outcomes 
    • Odds of facial nerve palsy with vaccination 

RESULTS: 

Case-control study 

  • 37 patients with facial nerve palsy (74 matched controls) 
    • 59.5% male | Mean (SD) age 50.9 (20.2) 
    • Recently vaccinated: 56.7% 
  • Facial nerve palsy onset among vaccinated patients  
    • Mean (SD) time from first dose: 9.3 (4.2) days (range 3 to 14) 
    • Mean (SD) time from second dose: 14.0 (12.6) days (range 1 to 23)  
  • There were no increased odds of vaccination exposure among those with facial nerve palsy 
    • Adjusted odds ratio 0.84 (95% CI, 0.37 to 1.90); P=0.67 
  • Analysis of the number of admissions for facial nerve palsy during the same period in preceding years (2015-2020)  
    • Stable trend with no increase in facial nerve palsy admission  

CONCLUSION: 

  • No association was found between COVID-19 vaccination with mRNA COVID-19 vaccines and risk for facial nerve palsy 
  • Another study by Renoud et al. (JAMA Intern Med, 2021) also explored this potential adverse event through a disproportionality analysis 
    • 133,883 cases of adverse drug reaction in mRNA COVID-19 pharmacovigilance database  
    • Cases of facial paralysis: 0.6% (844 patients)  
    • No signal of disproportionality of facial paralysis vs other vaccines or influenza vaccine specifically  
    • Risk is very low, and no higher when compared to other viral vaccines 
  • Shemer et al. conclude

In this case-control study, no association between acute facial nerve palsy and recent vaccination with the BNT162b2 vaccine was observed 

In addition, despite rapid and extensive vaccination of the population, a similar volume of admissions for facial nerve palsy was seen compared with the same period in preceding years 

Learn More – Primary Sources: 

Association of COVID-19 Vaccination and Facial Nerve Palsy: A Case-Control Study 

Association of Facial Paralysis With mRNA COVID-19 Vaccines: A Disproportionality Analysis Using the World Health Organization Pharmacovigilance Database 

image_pdfFavoriteLoadingFavorite
< Previous
All COVID-19 Management Posts
Next >

Related ObG Topics:

AstraZeneca and Pfizer Side Effects and Efficacy: Real World Data from the UK
An Update on COVID-19 Vaccine Related Anaphylaxis: Cases Remain Rare
How Common are Anaphylaxis and Allergic Reactions Following Pfizer-BioNTech COVID-19 Vaccination?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site